DCM
SGMO

DAFNA Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

DAFNA Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-225,000
Closed -$1.98M – 79
2017
Q2 		$1.98M Buy
+225,000
New +$1.44M 1.41% 23

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAFNA Capital Management's SGMO Position: Q3 2017 in Review

DAFNA Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2017, closing a stake of 225,000 shares — an estimated $1.98M sold.

DAFNA Capital Management first reported a position in SGMO in Q2 2017 and held it in 1 quarter. The position peaked at $1.98M in Q2 2017. 148 funds tracked by Wall St. Rank hold SGMO as of Q3 2017.

  • DAFNA Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 225,000 SANGAMO THERAPEUTICS INC shares in Q3 2017, an estimated $1.98M.
  • DAFNA Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and held it in 1 quarter.
  • DAFNA Capital Management's SANGAMO THERAPEUTICS INC position peaked at $1.98M in Q2 2017.
  • 148 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2017.

Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.